Tissue Regenix Group PLC (LON:TRX)‘s stock had its “speculative buy” rating reiterated by equities researchers at Beaufort Securities in a report issued on Thursday.

Separately, Jefferies Group upped their target price on Tissue Regenix Group PLC from GBX 35 ($0.43) to GBX 40 ($0.50) and gave the company a “buy” rating in a research report on Monday, July 11th.

Tissue Regenix Group PLC (LON:TRX) opened at 16.75 on Thursday. The company’s market cap is GBX 124.48 million. Tissue Regenix Group PLC has a 12-month low of GBX 12.70 and a 12-month high of GBX 22.50. The stock’s 50 day moving average price is GBX 19.31 and its 200 day moving average price is GBX 19.40.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/tissue-regenix-group-plc-trx-stock-rating-reaffirmed-by-beaufort-securities.html

About Tissue Regenix Group PLC

Tissue Regenix Group plc is a medical technology company. The Company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues. It operates through Cardiac, Wound Care and Orthopaedics divisions. Its decellularisation (dCELL) technology removes deoxyribonucleic acid and other cellular material from tissue leaving an acellular scaffold, which is not rejected by the patient’s body.

Receive News & Ratings for Tissue Regenix Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tissue Regenix Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.